Miguel Navasa

Universitat de Barcelona

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Antoni Rimola

Consorci Institut D'Investigacions Biomediques August Pi I Sunyer

Juan Carlos García‐Valdecasas

Hospital Clínic de Barcelona

Luís Grande

Hospital Del Mar

Juan Carlos García‐Pagán

Consorci Institut D'Investigacions Biomediques August Pi I Sunyer

Juan Rodés

Universitat de Barcelona

Vicente Arroyo

European Foundation for the Study of Chronic Liver Failure

J. Fuster

Universitat de Barcelona

Jaime Bosch

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas

Wladimiro Jiménez

Consorci Institut D'Investigacions Biomediques August Pi I Sunyer

Constantino Fondevila

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas

Cooperative Institutions

Universitat de Barcelona

225

Hospital Clínic de Barcelona

198

Consorci Institut D'Investigacions Biomediques August Pi I Sunyer

173

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas

156

Instituto de Salud Carlos III

Kyushu University

Centro de Investigación Biomédica en Red

University College London

Universitat Autònoma de Barcelona

Centre for Biomedical Network Research on Rare Diseases

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Table of contents

Gastroenterology (2006)

Richard M. Peek K. Rajender Reddy Rexford S. Ahima M Wallace Parvathi Rau

Table (database)

10.1053/s0016-5085(06)01953-6

Cite

Citations (0)

The association of isosorbide-5-mononitrate enhances the reduction in portal pressure caused by propranolol in patients with cirrhosis

Journal of Hepatology (1990)

Juan Carlos Garcı́a-Pagán Miguel Navasa Brú C Pilar Pizcueta Jaime Bosch

Isosorbide dinitrate

Isosorbide

Isosorbide mononitrate

10.1016/0168-8278(90)90089-a

Cite

Citations (2)

24 HIGHER SUSTAINED VIROLOGIC RESPONSE AND HISTOLOGIC IMPROVEMENT IN RECURRENT HEPATITIS C AFTER PEGYLATED INTERFERON PLUS RIBAVIRIN THERAPY UNDER CYCLOSPORINE-BASED VERSUS TACROLIMUS-BASED IMMUNOSUPPRESSIVE THERAPY

Journal of Hepatology (2010)

Miguel Navasa T. Casanovas Marina Berenguer I. Fernández Magdalena Salcedo

Pegylated interferon

Hepatitis C

Combination therapy

10.1016/s0168-8278(10)60026-8

Cite

Citations (1)

Bacterial infections in liver cirrhosis.

PubMed (1999)

Miguel Navasa J. Fernández J Rodés

The incidence of bacterial infections in cirrhotic patients admitted to hospital is very high. In several studies, 30% to 50% of cirrhotics presented bacterial infections at admission, or developed this type of complication during hospitalization. Most bacterial infections in cirrhotic patients are hospital-acquired. Between 15% to 35% of cirrhotics admitted to hospital develop nosocomial infections; these figures contrast sharply with the hospital-acquired infection rate in the general hospital population (5% to 7%). Urinary tract infections (12% to 29%), spontaneous bacterial peritonitis (7% to 23%), respiratory tract infections (6% to 10%) and bacteraemia (4% to 9%) are the most frequent bacterial infectious complications seen in cirrhotic patients. However, since spontaneous bacterial peritonitis is the most characteristic bacterial infection in cirrhosis, this report will focus (mainly) on this infectious complication.

Spontaneous bacterial peritonitis

Source

Cite

Citations (75)

Hepatitis C virus superinfection of liver grafts: a detailed analysis of early exclusion of non-dominant virus strains

Journal of General Virology (2010)

Santseharay Ramírez Sofía Pérez‐del‐Pulgar J.A. Carrión Mairene Coto‐Llerena L. Mensa

Liver transplantation (LT) of hepatitis C virus (HCV)-infected grafts into HCV-infected recipients leads to superinfection with two different virus strains. To characterize the virological outcomes of HCV superinfection immediately after LT, we performed phylogenetic analysis of a fragment of the NS5B gene in donor and recipient serum samples prospectively collected before and after LT, starting on day 1. In four of six cases, the donor strain finally prevailed, while in the remaining two cases, the native recipient strain overtook the donor quasispecies. Clonal sequence analysis showed that, in three cases, the expelled strain was undetectable 1 day after LT. Our study shows that superinfection with a different HCV strain can lead to the exclusion of one strain by the other as soon as the first day after LT. This would suggest that competition might not be limited to the replication level, but could also take place during virus entry.

Superinfection

Viral quasispecies

NS5B

Strain (injury)

10.1099/vir.0.018929-0

Cite

Citations (37)

Prospective Evaluation of Single-Operator Peroral Cholangioscopy in Liver Transplant Recipients Requiring an Evaluation of the Biliary Tract

Liver Transplantation (2013)

Domingo Balderramo Oriol Sendino Rosa Miquel Cristina Rodríguez de Miguel Josep M. Bordas

In this descriptive study, we examined the role of single-operator cholangioscopy (SOC) in the evaluation of biliary complications after liver transplantation (LT). We prospectively included adult recipients of deceased donor LT who were referred for endoscopic retrograde cholangiopancreatography between June 2009 and July 2011. All patients underwent SOC with biopsy of the biliary anastomosis. Sixteen patients were included: 12 with biliary anastomotic strictures (ASs), 2 with common bile duct stones, 1 with a bile leak, and 1 with sphincter of Oddi dysfunction. Patients with ASs displayed 1 of 2 patterns: (A) mild erythema (n = 9) or (B) edema, ulceration, and sloughing (n = 3). Those without ASs displayed a pale mucosa with mild edema at the anastomosis. Patients with ASs and pattern B required a longer period of stenting than patients with pattern A (457 versus 167 days, P = 0.01). In addition, patients with pattern A had a better response and better resolution of their strictures with endoscopic therapy than those with pattern B (88.9% versus 33.4%, P = 0.13). Histological examinations of ASs showed nonspecific intraepithelial inflammation in patients with patterns A and B. Biopsy samples from patients without ASs showed normal columnar epithelial bile duct cells. The total cholangioscopy time for all procedures was 26.8 ± 10.1 minutes. In conclusion, SOC in LT recipients is feasible and allows adequate visualization and tissue sampling of ASs and bile ducts. Two distinct visual patterns that are easily identified with SOC may help to predict the outcomes of endoscopic therapy in patients with biliary complications after LT. Liver Transpl 19:199-206, 2013. © 2012 AASLD.

10.1002/lt.23585

Cite

Citations (31)

766 Early lobular necrosis and living donor liver transplantation are strong predictors of severe HCV recurrence after liver

Hepatology (2003)

Montserrat García–Retortillo Xavier Forns J LLOVET Miguel Navasa Juan Turnés

Hepatitis C recurrence after liver transplantation (LT) is the main problem of most transplant programs. We aimed at assessing the antiviral activity and safety of intravenous silibinin (SIL) administered daily during the peri-transplant period.This was a single-centre, prospective, randomized, double-blind, placebo-controlled study including 14 HCV-infected patients awaiting LT. Eleven patients received SIL and 3 placebo, for a maximum of 21 days before LT and 7 days after LT.Among the patients who received more than 14 days of pre-LT treatment, the median decrease in viral load (VL) was 2.31 log10 (range 0.6–4.2) in the SIL-treated group (n = 9) versus 0.30 log10 (0.1–0.6) in the placebo group (n = 3) (p = 0.016). During the post-LT treatment, HCV-RNA levels were consistently and significantly (p = 0.002) lower in the SIL group compared to placebo and decreased below the limit of quantification in 2 patients and below the limit of detection in 2 additional patients (all in the SIL-treated group). Peri-transplant treatment with SIL was well tolerated.This proof-of-concept study in patients in the waiting list for LT indicates that daily intravenous silibinin has evident antiviral properties and is well tolerated in the peri-LT period. A longer treatment regimen with silibinin (alone or in combination with other agents) should be assessed in clinical trials for the prevention of hepatitis C recurrence.

Silibinin

Hepatitis C

Regimen

10.1016/s0270-9139(03)80808-x

Cite

Citations (0)

Liver Transplantation and Quality of Life

Miguel Navasa Juan Rodés

10.1002/9780470691861.ch25g

Cite

Citations (0)

Bacterial Infections in Portal Hypertension

Javier Fernández Miguel Navasa

10.1002/9780470691861.ch7i

Cite

Citations (0)

Determinants of Ethanol and Acetaldehyde Metabolism in Chronic Alcoholics

Alcoholism Clinical and Experimental Research (1993)

Julían Panés Joan Caballería Raimón Guitart Albert Parés Xavier Soler

We have studied the factors determining the rate of ethanol and acetaldehyde metabolism in a group of 25 alcoholics with varying degrees of liver lesion (from normal liver to cirrhosis) and in six nonalcoholic cirrhotics. In alcoholics the ethanol metabolic rate was related to hepatic function, estimated either by the aminopyrine breath test (r = 0.70, p < 0.001) or the indocyanine green clearance (r = 0.76, p < 0.01), and was independent of the activity of hepatic alcohol dehydrogenase and hepatic blood flow. In nonalcoholic cirrhotics blood acetaldehyde was always below the detection limit (0.5 microM), but elevated levels were found in 14 out of the 25 alcoholics. Alcoholics with elevated blood acetaldehyde showed a significantly higher ethanol metabolic rate than alcoholics with undetectable acetaldehyde (120 +/- 17 mg/kg/hr vs 104 +/- 11 mg/kg/hr, p < 0.02), but no differences were observed in the activities of alcohol and aldehyde dehydrogenases. Peak blood acetaldehyde levels were directly related to the ethanol metabolic rate (r = 0.48, p < 0.02), but not to activities of hepatic alcohol or aldehyde dehydrogenases. These results indicate that in chronic alcoholics the main determinant of the ethanol metabolic rate is hepatic function, while the rise of blood acetaldehyde is mainly dependent on the ethanol metabolic rate. Alcohol and aldehyde dehydrogenase activities do not seem to be rate-limiting factors in the oxidation of ethanol or acetaldehyde.

Ethanol metabolism

10.1111/j.1530-0277.1993.tb00725.x

Cite

Citations (38)